The global stem cell anticancer therapeutics market was valued at $859 million in 2010. This market is expected to increase at an 11.3% compound annual growth rate (CAGR) to reach nearly $1.5 billion in 2015.
This study examines the human applications both marketed and in development of anti–cancer and tissue protective therapies and stem cell therapies for oncology conditions. BCC extensively analyzes each market segment, presents its current market status and presents various forecasts for growth over the next 5 years. Other factors such as Food and Drug Administration (FDA) restrictions, government legislation, a cancer’s drug resistance to therapeutics, and/or natural and alternative remedies are also highlighted, where they meet the criteria of what this report is defining as a stem cell based therapeutic. Our financial and sales analysis focuses on the available figures from 2007 through 2009 with estimates for the years 2010 through 2015, including compound annual growth rates (CAGRs).
Michael Delander is a biotechnology research consultant with more than 15 years of research experience. Michael has been consulting with venture capital based start–ups and larger industry alike since 2003, and has focused on in–depth research in a wide range of medical therapeutics in early development. His key published work is located in national and international organizations including the National Library of Medicine, the University of California as well as numerous Ivy–league libraries.